Shuttle Pharmaceuticals dismisses Forvis Mazars as auditor
SHPH•Shuttle Pharmaceuticals will dismiss Forvis Mazars after filing its quarterly report for the period ended September 30, 2026. The auditor’s 2024 and 2025 reports flagged substantial doubt about the company’s ability to continue as a going concern.
1. Auditor dismissal
Shuttle Pharmaceuticals’ board approved the dismissal of Forvis Mazars on October 16, 2026. It will take effect after the company files its quarterly report for the period ended September 30, 2026.
2. Audit findings
Forvis Mazars’ audit reports for 2024 and 2025 flagged substantial doubt about the company’s ability to continue as a going concern. Disclosed material weaknesses covered financial reporting controls, IT controls and insufficient technical accounting expertise for complex transactions. The company reported no accounting or auditing disagreements during 2025, 2024 or the interim period through October 16, 2026.
